Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy

被引:13
|
作者
Mossanen, Matthew [1 ]
Carvalho, Filipe L. F. [1 ]
Muralidhar, Vinayak [2 ,6 ]
Preston, Mark A. [1 ]
Reardon, Brendan [3 ]
Conway, Jake R. [3 ]
Curran, Catherine [3 ]
Freeman, Dory [3 ]
Sha, Sybil [4 ]
Sonpavde, Guru [3 ]
Hirsch, Michelle [5 ]
Kibel, Adam S. [1 ]
Van Allen, Eliezer M. [3 ]
Mouw, Kent W. [2 ]
机构
[1] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Div Urol Surg, Boston, MA 02115 USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
[3] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[4] Geisel Sch Med Dartmouth, Hanover, NH USA
[5] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[6] Kaiser Permanente Northwest, Portland, OR USA
关键词
Prostate cancer; Bladder cancer; Radiation; Radiation-associated cancer; Second malignancy; DNA sequencing; Genomics; Mutational signatures; SOMATIC ERCC2 MUTATIONS; 2ND MALIGNANCIES; SIGNATURES; RADIATION; OUTCOMES; THERAPY; SAMPLES; RISK;
D O I
10.1016/j.eururo.2021.12.004
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Muscle-invasive bladder cancer (MIBC) is a rare but serious event following definitive radiation for prostate cancer. Radiation-associated MIBC (RA-MIBC) can be difficult to manage given the challenges of delivering definitive therapy to a previously irradiated pelvis. The genomic landscape of RA-MIBC and whether it is distinct from non-RA-MIBC are unknown. Objective: To define mutational features of RA-MIBC and compare the genomic landscape of RA-MIBC with that of non-RA-MIBC. Design, setting, and participants: We identified patients from our institution who received radiotherapy for prostate cancer and subsequently developed MIBC. Outcome measurements and statistical analysis: We performed whole exome sequencing of bladder tumors from RA-MIBC patients. Tumor genetic alterations including mutations, copy number alterations, and mutational signatures were identified and were compared with genetic features of non-RA-MIBC. We used the Kaplan-Meier method to estimate recurrence-free (RFS) and overall (OS) survival. Results and limitations: We identified 19 RA-MIBC patients with available tumor tissue (n = 22 tumors) and clinical data. The median age was 76 yr, and the median time from prostate cancer radiation to RA-MIBC was 12 yr. The median RFS was 14.5 mo and the median OS was 22.0 mo. Compared with a cohort of non-RA-MIBC analyzed in parallel, there was no difference in tumor mutational burden, but RA-MIBCs had a significantly increased number of short insertions and deletions (indels) consistent with previous radiation exposure. We identified mutation signatures characteristic of APOBEC-mediated mutagenesis, aging, and homologous recombination deficiency. The frequency of mutations in many known bladder cancer genes, including TP53, KDM6A, and RB1, as well as copy number alterations such as CDKN2A loss was similar in RA-MIBC and non-RA-MIBC. Conclusions: We identified unique mutational properties that likely contribute to the distinct biological and clinical features of RA-MIBC. Patient summary: Bladder cancer is a rare but serious diagnosis following radiation for prostate cancer. We characterized genetic features of bladder tumors arising after prostate radiotherapy, and identify similarities with and differences from bladder tumors from patients without previous radiation. (C) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:466 / 473
页数:8
相关论文
共 50 条
  • [1] Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy: A Rare Entity with Unique Genomic Features
    Braun, Avery
    Abbosh, Phillip H.
    EUROPEAN UROLOGY, 2022, 81 (05) : 474 - 475
  • [2] Muscle-invasive bladder cancer following radiotherapy for prostate adenocarcinoma
    Barnett, Jack
    Bruha, Matthew
    Ozay, Fatih
    Hyacinthe, Llewellyn
    UROLOGY CASE REPORTS, 2021, 34
  • [3] Genomic Features of Radiation-Associated Muscle-Invasive Bladder Cancer
    Muralidhar, V.
    Carvalho, F.
    Preston, M.
    Curran, C.
    Freeman, D.
    Sonpavde, G.
    Kibel, A.
    Van Allen, E. M.
    Mossanen, M.
    Mouw, K. W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S13 - S14
  • [5] Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer
    Pignot, G.
    Sargos, P.
    PROGRES EN UROLOGIE, 2021, 31 (03): : 158 - 168
  • [6] Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer
    Chyle, V
    Pollack, A
    Czerniak, B
    Stephens, LC
    Zagars, GK
    Terry, NHA
    Meyn, RE
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 35 (02): : 281 - 287
  • [7] Genomic Characterization of Radiotherapy-Associated Muscle invasive Bladder Cancer after Prostate Cancer Treatment
    Wijetunga, N. A.
    Gessner, K. H.
    Repka, M. C.
    Sud, S.
    Kanchi, K.
    Wobker, S. E.
    Corcoran, D.
    Galsky, M.
    Milowsky, M.
    Kim, W. Y.
    Rose, T. L.
    Damrauer, J. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S198 - S199
  • [8] Radiotherapy plus Chemotherapy in Muscle-Invasive Bladder Cancer
    Atkins, Carl D.
    Wrzesinski, Stephen H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (04): : 380 - 380
  • [9] Radiotherapy With or Without Chemotherapy in Muscle-invasive Bladder Cancer
    Bagrodia, Aditya
    Lotan, Yair
    EUROPEAN UROLOGY, 2013, 63 (03) : 580 - 581
  • [10] Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer
    James, Nicholas D.
    Hussain, Syed A.
    Hall, Emma
    Jenkins, Peter
    Tremlett, Jean
    Rawlings, Christine
    Crundwell, Malcolm
    Sizer, Bruce
    Sreenivasan, Thiagarajan
    Hendron, Carey
    Lewis, Rebecca
    Waters, Rachel
    Huddart, Robert A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (16): : 1477 - 1488